St. Jude Medical Inc. announced U.S. Food and Drug Administration (FDA) approval to begin the EnligHTN IV Renal Denervation Study, the first U.S. trial using the EnligHTN Multi-Electrode Renal Denervation System to treat patients with drug-resistant high blood pressure.


Abbott has announced publication of positive outcomes from two European post-approval studies of the catheter-based MitraClip therapy for the treatment of mitral regurgitation (MR). Results from ACCESS-EU, a European prospective study that enrolled 567 patients at 14 sites, have been published in the Journal of the American College of Cardiology. In addition, findings of the investigator-sponsored German TRAnscatheter Mitral Valve Interventions (TRAMI) registry, which enrolled 1,064 patients at 20 German sites, were recently published in EuroIntervention.

Tryton Medical Inc. announced that the Nordic-Baltic Bifurcation Study Group will investigate the Tryton Side Branch Stent. The trial is a prospective, controlled, randomized, multicenter clinical study examining the role of final kissing balloon inflations in patient outcomes. A total of 150 patients will receive the Tryton Side Branch Stent with a drug-eluting stent, with evaluation by intravascular optical coherence tomography (OCT) imaging technology.

Mirada Medical collaborators has presented new positron emission tomography/magnetic resonance imaging (PET/MRI) research. The software supports both the hardware hybrid scanners and provides validated deformable registration for software based PET/CT (computed tomorgraphy)/MRI.

MIM Software Inc. has introduced a new version of MIM Encore that provides a single platform for viewing positron emission tomography (PET), computed tomography (CT), magnetic resonance imaging (MRI) and nuclear medicine exams.  Users will benefit from having all of the imaging data they need available on one workstation.  Additionally, integrated quantitative analysis solutions are available for both cardiac and neuro PET and single photon emission computed tomography (SPECT) providing an all-in-one solution for Nuclear Medicine departments.

Siemens Healthcare has introduced the world’s first xSPECT system — combines the high sensitivity of single-photon emission computed tomography (SPECT) with the high specificity of computed tomography (CT), completely integrating the data from the two modalities, to generate high resolution and quantitative images. Meanwhile, Biograph mCT Flow is a new positron emission tomography/computed tomography (PET/CT) system that overcomes the limitations of conventional bed-based PET/CT with FlowMotion. This new technology moves the patient smoothly through the system’s gantry, while continuously acquiring PET data.

UltraSPECT announced the installation of its proprietary Wide Beam Reconstruction (WBR) software at nearly 10 healthcare facilities. The installations came as a result of the recent agreement between UltraSPECT and radiopharmaceutical provider PharmaLogic, under which PharmaLogic offers the WBR software as part of its patient-centered approach.

Siemens Healthcare has introduced Biograph mCT Flow, a positron emission tomography/computed tomography (PET/CT) system that, for the first time ever, overcomes the limitations of conventional bed-based PET/CT with FlowMotion, a revolutionary new technology that moves the patient smoothly through the system’s gantry, while continuously acquiring PET data. Biograph mCT Flow with FlowMotion takes routine image quality to a new level by enabling imaging protocols based on the organ’s need.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now